biguanides has been researched along with Nausea in 4 studies
Biguanides: Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES.
biguanides : A class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.
Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Weight loss was greater in patients with lower baseline HbA1c and in patients taking concomitant biguanides." | 5.22 | Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes. ( Iwamoto, N; Nishiyama, H; Ohyama, S; Onishi, Y; Oura, T; Takeuchi, M, 2016) |
| "Preclinical models suggest anticancer activity of IM156, a novel biguanide mitochondrial protein complex 1 inhibitor of oxidative phosphorylation (OXPHOS)." | 3.11 | First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors. ( Beom, SH; Cheong, JH; Geiger, B; Janku, F; Kim, GM; Kim, HS; Kim, SY; Kim, TW; Lee, YW; Moon, YW; Rha, SY; Rudoltz, MS; Shin, YG; Thurston, A; Welsch, D; Yim, DS; Yoo, S, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Janku, F | 1 |
| Beom, SH | 1 |
| Moon, YW | 1 |
| Kim, TW | 1 |
| Shin, YG | 1 |
| Yim, DS | 1 |
| Kim, GM | 1 |
| Kim, HS | 1 |
| Kim, SY | 1 |
| Cheong, JH | 1 |
| Lee, YW | 1 |
| Geiger, B | 1 |
| Yoo, S | 1 |
| Thurston, A | 1 |
| Welsch, D | 1 |
| Rudoltz, MS | 1 |
| Rha, SY | 1 |
| Onishi, Y | 1 |
| Oura, T | 1 |
| Nishiyama, H | 1 |
| Ohyama, S | 1 |
| Takeuchi, M | 1 |
| Iwamoto, N | 1 |
| Tuerke, KJ | 1 |
| Limebeer, CL | 1 |
| Fletcher, PJ | 1 |
| Parker, LA | 1 |
| Bäbler, M | 1 |
2 trials available for biguanides and Nausea
| Article | Year |
|---|---|
First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors.
Topics: Antineoplastic Agents; Biguanides; Dose-Response Relationship, Drug; Humans; Maximum Tolerated Dose; | 2022 |
Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes.
Topics: Aged; Biguanides; Body Mass Index; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Blin | 2016 |
2 other studies available for biguanides and Nausea
| Article | Year |
|---|---|
Double dissociation between regulation of conditioned disgust and taste avoidance by serotonin availability at the 5-HT(3) receptor in the posterior and anterior insular cortex.
Topics: 5,6-Dihydroxytryptamine; Animals; Avoidance Learning; Biguanides; Cerebral Cortex; Conditioning, Cla | 2012 |
[Diabetes mellitus and obesity: monotherapy using biguanides].
Topics: Adult; Biguanides; Body Weight; Child; Diabetes Mellitus; Diarrhea; Diet Therapy; Flatulence; Humans | 1973 |